The use of small-molecule inhibitors to study molecular components of cellular signal transduction pathways provides a means of analysis complementary to currently used techniques, such as antisense, dominantnegative (interfering) mutants and constitutively activated mutants. We have identified and characterized a small-molecule inhibitor, SU6656, which exhibits selectivity for Src and other members of the Src family. A related inhibitor, SU6657, inhibits many kinases, including Src and the platelet-derived growth factor (PDGF) receptor. The use of SU6656 confirmed our previous findings that Src family kinases are required for both Myc induction and DNA synthesis in response to PDGF stimulation of NIH 3T3 fibroblasts. By comparing PDGFstimulated tyrosine phosphorylation events in untreated and SU6656-treated cells, we found that some substrates (for example, c-Cbl, and protein kinase C ␦) were Src family substrates whereas others (for example, phospholipase C-␥) were not. One protein, the adaptor Shc, was a substrate for both Src family kinases (on tyrosines 239 and 240) and a distinct tyrosine kinase (on tyrosine 317, which is perhaps phosphorylated by the PDGF receptor itself). Microinjection experiments demonstrated that a Shc molecule carrying mutations of tyrosines 239 and 240, in conjunction with an SH2 domain mutation, interfered with PDGF-stimulated DNA synthesis. Deletion of the phosphotyrosine-binding domain also inhibited synthesis. These inhibitions were overcome by heterologous expression of Myc, supporting the hypothesis that Shc functions in the Src pathway. SU6656 should prove a useful additional tool for further dissecting the role of Src kinases in this and other signal transduction pathways.

The 11;22 chromosomal translocation specificaOly linked to Ewing sarcoma and primitive neuroectodermal tumor results in a chimeric molecule fusing the aminoterminal-encoding portion of the EWS gene to the carboxylterminal DNA-binding domain encoded by the FLII gene. We have isolated a fourth EWS-FLII fusion cDNA that is structurally distinct from the three forms previously described. To determine the transforming activity of this gene, alternative forms of the EWS-FLI1 fusion were transduced into NIH 3T3 Structural alteration or aberrant expression of transcription factors is also common in human malignancies but usually results through somatic genomic mutation (for reviews, see refs. 2 and 3). Karyotypic analyses have revealed a tumor-specific t(11;22)(q24;ql2) chromosomal translocation in 86% of both Ewing sarcoma and primitive neuroectodermal tumor (PNET), suggesting that the product of this rearrangement is necessary for the formation of both these malignancies (4,5 MATERIALS AND METHODSPNET cDNA Library Construction and Isolation of EWS-FL!) Chimeras. TC-32, a PNET tumor cell line containing the 11;22 translocation, was grown in RPMI medium/10% fetal calf serum, as described (5). Total RNA was harvested by lysis with guanidine isothiocyanate and purified over cesium chloride (9). Poly(A)+ RNA was obtained by using columns packed with oligo(dT)-cellulose (Collaborative Research) and used for construction of cDNA libraries.A TC-32 cDNA library was made according to previously published procedures (10). Briefly, first-strand synthesis was accomplished using methyl mercury-denatured poly(A)+ RNA primed with oligo(dT) and murine leukemia virus reverse transcriptase (GIBCO/BRL). Second-strand synthesis was done by using RNase H and polymerase I (GIBCO/ BRL), and synthesized products were purified over a Sephadex G100 column (Pharmacia). cDNAs were blunted by using T4 polymerase (GIBCO/BRL) and ligated to a molar excess of EcoRI adaptors (Invitrogen, San Diego). The adaptor ends were phosphorylated with T4 polynucleotide kinase (United States Biochemical), and cDNAs were fractionated over a 6% acrylamide gel. DNA species >600 bp were recovered from gel slices by electroelution, purified over

No abstract

The late stages of human breast cancer development are poorly understood complex processes associated with the expression of genes by cancers that promote specific tumorigenic activities, such as angiogenesis. Here, we describe the identification of periostin as a mesenchyme-specific gene whose acquired expression by human breast cancers leads to a significant enhancement in tumor progression and angiogenesis. Undetectable in normal human breast tissues, periostin was found to be overexpressed by the vast majority of human primary breast cancers examined. Tumor cell lines engineered to overexpress periostin showed a phenotype of accelerated growth and angiogenesis as xenografts in immunocompromised animals. The underlying mechanism of periostin-mediated induction of angiogenesis was found to derive in part from the up-regulation of the vascular endothelial growth factor receptor Flk-1/KDR by endothelial cells through an integrin ␣ v ␤ 3 -focal adhesion kinase-mediated signaling pathway. These findings demonstrate the presence of a novel mechanism by which tumor angiogenesis is acquired with the expression of a mesenchyme-specific gene as a crucial step in late stages of tumorigenesis.

In contrast to signal generation and transmission, the mechanisms and molecules that negatively regulate receptor tyrosine kinase (RTK) signaling are poorly understood. Here we characterize Mig-6 as a novel negative feedback regulator of the epidermal growth factor receptor (EGFR) and potential tumor suppressor. Mig-6 was identified in a yeast two-hybrid screen with the kinase active domain of the EGFR as bait. Upon EGF stimulation Mig-6 binds to the EGFR involving a highly acidic region between amino acids 985-995. This interaction is kinase activity-dependent, but independent of tyrosine 992. Mig-6 overexpression results in reduced activation of the mitogenactivated protein kinase ERK2 in response to EGF, but not FGF or PDGF, stimulation and in enhanced receptor internalization without affecting the rate of degradation. The induction of Mig-6 mRNA expression in response to EGF, but not FGF, indicates the existence of a negative regulatory feedback loop. Consistent with these findings, a possible role as tumor suppressor is indicated by Mig-6-mediated inhibition of EGFR overexpression-induced transformation of Rati cells.